An Introduction to REBYOTA® (fecal microbiota, live - jslm), the Patient Experience & Administration Training

image

This session will provide an in-depth exploration of the role the microbiome plays in overall health and its impact on the pathogenesis and recurrence of Clostridioides difficile infection (rCDI). Attendees will gain a comprehensive understanding of the mechanisms behind rCDI, including the significant burden it places on patients both during and after acute infection.

We will delve into the microbial composition, potency, and standardized manufacturing process of REBYOTA® (fecal microbiota, live-jslm), an FDA-approved therapeutic option for rCDI. Participants will have the opportunity to review key efficacy and safety data from clinical trials, providing evidence of REBYOTA® in clinical settings.
Through patient case studies, we will also discuss the practical application of REBYOTA® in real-world clinical practice, offering valuable insights into its role in managing and preventing rCDI recurrence. This session is ideal for health care professionals looking to deepen their knowledge of microbiome-related diseases and explore innovative treatments for recurrent CDI.

Learning Objectives: At the conclusion of this session, learners will be able to: 

• Understand the role of the microbiome in overall health, pathogenesis of Clostridioides difficile infection (CDI), and the burden of rCDI
• Learn about REBYOTA®, review efficacy and safety data, and discuss patient case studies
• Review step-by-step how to administer REBYOTA® 

This webinar does not offer any continuing education credits or recertification units. 

Candace L. Cotto, RN

Candace Cotto, RN, has been a nurse for 45 years. She started her career as a critical care nurse, then switched focus to research at the YALE Cancer Center. She's been a research nurse in Gastroenterology for 10 years, with a focus on Clostridioides difficile infection (CDI) clinical trials and has worked on REBYOTA® trials since 2017; the most recent trial being the PUNCH CD3-OLS trial, which led to US Food and Drug Administration (FDA) approval in November 2022. She has performed over 120 REBYOTA procedures. Ms Cotto has spoken in numerous forums on recurrent CDI (rCDI) and was published in Gastroenterology Nurse, Sep-Oct 2024 (Prevention of Recurrent Clostridioides difficile Infection: What Gastroenterology Nurses Need to Know). She has been on the Speaker Board for REBYOTA with Ferring Pharmaceuticals since it received FDA approval.

Key:

Complete
Failed
Available
Locked
An Introduction to REBYOTA® (fecal microbiota, live - jslm), the Patient Experience & Administration Training
Live event: 03/26/2025 at 1:00 PM (EDT) You must register to access.
Webinar Evaluation
You must register to access.